A citation-based method for searching scientific literature

Lukas Bubendorf, Reinhard Büttner, Fouad Al-Dayel, Manfred Dietel, Göran Elmberger, Keith Kerr, Fernando López-Ríos, Antonio Marchetti, Büge Öz, Patrick Pauwels, Frédérique Penault-Llorca, Giulio Rossi, Aleš Ryška, Erik Thunnissen. Virchows Arch 2016
Times Cited: 137







List of co-cited articles
801 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Crizotinib in ROS1-rearranged non-small-cell lung cancer.
Alice T Shaw, Sai-Hong I Ou, Yung-Jue Bang, D Ross Camidge, Benjamin J Solomon, Ravi Salgia, Gregory J Riely, Marileila Varella-Garcia, Geoffrey I Shapiro, Daniel B Costa,[...]. N Engl J Med 2014
39

ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas.
Lynette M Sholl, Heather Sun, Mohit Butaney, Chengsheng Zhang, Charles Lee, Pasi A Jänne, Scott J Rodig. Am J Surg Pathol 2013
130
31

ROS1 rearrangements define a unique molecular class of lung cancers.
Kristin Bergethon, Alice T Shaw, Sai-Hong Ignatius Ou, Ryohei Katayama, Christine M Lovly, Nerina T McDonald, Pierre P Massion, Christina Siwak-Tapp, Adriana Gonzalez, Rong Fang,[...]. J Clin Oncol 2012
29

Comparison of Molecular Testing Modalities for Detection of ROS1 Rearrangements in a Cohort of Positive Patient Samples.
Kurtis D Davies, Anh T Le, Jamie Sheren, Hala Nijmeh, Katherine Gowan, Kenneth L Jones, Marileila Varella-Garcia, Dara L Aisner, Robert C Doebele. J Thorac Oncol 2018
101
25

Immunohistochemical detection of ROS1 is useful for identifying ROS1 rearrangements in lung cancers.
Akihiko Yoshida, Koji Tsuta, Susumu Wakai, Yasuhito Arai, Hisao Asamura, Tatsuhiro Shibata, Koh Furuta, Takashi Kohno, Ryoji Kushima. Mod Pathol 2014
99
22

Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.
Julien Mazières, Gérard Zalcman, Lucio Crinò, Pamela Biondani, Fabrice Barlesi, Thomas Filleron, Anne-Marie C Dingemans, Hervé Léna, Isabelle Monnet, Sacha I Rothschild,[...]. J Clin Oncol 2015
251
22

RET, ROS1 and ALK fusions in lung cancer.
Kengo Takeuchi, Manabu Soda, Yuki Togashi, Ritsuro Suzuki, Seiji Sakata, Satoko Hatano, Reimi Asaka, Wakako Hamanaka, Hironori Ninomiya, Hirofumi Uehara,[...]. Nat Med 2012
916
21

Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer.
Yi-Long Wu, James Chih-Hsin Yang, Dong-Wan Kim, Shun Lu, Jianying Zhou, Takashi Seto, Jin-Ji Yang, Noboru Yamamoto, Myung-Ju Ahn, Toshiaki Takahashi,[...]. J Clin Oncol 2018
166
20

On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.
Lénaïg Mescam-Mancini, Sylvie Lantuéjoul, Denis Moro-Sibilot, Isabelle Rouquette, Pierre-Jean Souquet, Clarisse Audigier-Valette, Jean-Christophe Sabourin, Chantal Decroisette, Linda Sakhri, Elisabeth Brambilla,[...]. Lung Cancer 2014
95
20


Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.
Klarisa Rikova, Ailan Guo, Qingfu Zeng, Anthony Possemato, Jian Yu, Herbert Haack, Julie Nardone, Kimberly Lee, Cynthia Reeves, Yu Li,[...]. Cell 2007
18

Molecular pathways: ROS1 fusion proteins in cancer.
Kurtis D Davies, Robert C Doebele. Clin Cancer Res 2013
224
18

Identifying and targeting ROS1 gene fusions in non-small cell lung cancer.
Kurtis D Davies, Anh T Le, Mariana F Theodoro, Margaret C Skokan, Dara L Aisner, Eamon M Berge, Luigi M Terracciano, Federico Cappuzzo, Matteo Incarbone, Massimo Roncalli,[...]. Clin Cancer Res 2012
305
18


Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
Alexander Drilon, Salvatore Siena, Sai-Hong Ignatius Ou, Manish Patel, Myung Ju Ahn, Jeeyun Lee, Todd M Bauer, Anna F Farago, Jennifer J Wheler, Stephen V Liu,[...]. Cancer Discov 2017
475
17

Detection of ROS1 gene rearrangement in lung adenocarcinoma: comparison of IHC, FISH and real-time RT-PCR.
Ling Shan, Fang Lian, Lei Guo, Tian Qiu, Yun Ling, Jianming Ying, Dongmei Lin. PLoS One 2015
68
23

Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
Alice T Shaw, Enriqueta Felip, Todd M Bauer, Benjamin Besse, Alejandro Navarro, Sophie Postel-Vinay, Justin F Gainor, Melissa Johnson, Jorg Dietrich, Leonard P James,[...]. Lancet Oncol 2017
394
15

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
Alexander Drilon, Theodore W Laetsch, Shivaani Kummar, Steven G DuBois, Ulrik N Lassen, George D Demetri, Michael Nathenson, Robert C Doebele, Anna F Farago, Alberto S Pappo,[...]. N Engl J Med 2018
15

Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement.
Sun Min Lim, Hye Ryun Kim, Jong-Seok Lee, Ki Hyeong Lee, Yun-Gyoo Lee, Young Joo Min, Eun Kyung Cho, Sung Sook Lee, Bong-Seog Kim, Moon Young Choi,[...]. J Clin Oncol 2017
191
15

Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non-Small Cell Lung Carcinoma: the ROSING Study.
Esther Conde, Susana Hernandez, Rebeca Martinez, Barbara Angulo, Javier De Castro, Ana Collazo-Lorduy, Beatriz Jimenez, Alfonso Muriel, Jose Luis Mate, Teresa Moran,[...]. J Thorac Oncol 2019
38
39

ROS1 immunohistochemistry among major genotypes of non-small-cell lung cancer.
Theresa A Boyle, Katsuhiro Masago, Kim E Ellison, Yasushi Yatabe, Fred R Hirsch. Clin Lung Cancer 2015
43
32

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
Manabu Soda, Young Lim Choi, Munehiro Enomoto, Shuji Takada, Yoshihiro Yamashita, Shunpei Ishikawa, Shin-ichiro Fujiwara, Hideki Watanabe, Kentaro Kurashina, Hisashi Hatanaka,[...]. Nature 2007
14

Identification of ALK, ROS1, and RET Fusions by a Multiplexed mRNA-Based Assay in Formalin-Fixed, Paraffin-Embedded Samples from Advanced Non-Small-Cell Lung Cancer Patients.
Noemí Reguart, Cristina Teixidó, Ana Giménez-Capitán, Laia Paré, Patricia Galván, Santiago Viteri, Sonia Rodríguez, Vicente Peg, Erika Aldeguer, Nuria Viñolas,[...]. Clin Chem 2017
46
30

Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions.
Jaclyn F Hechtman, Ryma Benayed, David M Hyman, Alexander Drilon, Ahmet Zehir, Denise Frosina, Maria E Arcila, Snjezana Dogan, David S Klimstra, Marc Ladanyi,[...]. Am J Surg Pathol 2017
247
14

Novel targets in non-small cell lung cancer: ROS1 and RET fusions.
Justin F Gainor, Alice T Shaw. Oncologist 2013
235
14

Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001.
A T Shaw, G J Riely, Y-J Bang, D-W Kim, D R Camidge, B J Solomon, M Varella-Garcia, A J Iafrate, G I Shapiro, T Usari,[...]. Ann Oncol 2019
176
14

Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion.
Victoria M Rimkunas, Katherine E Crosby, Daiqiang Li, Yerong Hu, Meghan E Kelly, Ting-Lei Gu, Jennifer S Mack, Matthew R Silver, Xinmin Zhou, Herbert Haack. Clin Cancer Res 2012
204
13

First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
Benjamin J Solomon, Tony Mok, Dong-Wan Kim, Yi-Long Wu, Kazuhiko Nakagawa, Tarek Mekhail, Enriqueta Felip, Federico Cappuzzo, Jolanda Paolini, Tiziana Usari,[...]. N Engl J Med 2014
13

Recent Advances in Targeting ROS1 in Lung Cancer.
Jessica J Lin, Alice T Shaw. J Thorac Oncol 2017
134
13

Multicenter Evaluation of a Novel ROS1 Immunohistochemistry Assay (SP384) for Detection of ROS1 Rearrangements in a Large Cohort of Lung Adenocarcinoma Patients.
Véronique Hofman, Isabelle Rouquette, Elodie Long-Mira, Nicolas Piton, Emmanuel Chamorey, Simon Heeke, Jean Michel Vignaud, Clémence Yguel, Julien Mazières, Anne-Laure Lepage,[...]. J Thorac Oncol 2019
26
50

ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research.
C Marchiò, M Scaltriti, M Ladanyi, A J Iafrate, F Bibeau, M Dietel, J F Hechtman, T Troiani, F López-Rios, J-Y Douillard,[...]. Ann Oncol 2019
165
13

Screening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target.
Christina I Selinger, Bob T Li, Nick Pavlakis, Matthew Links, Anthony J Gill, Adrian Lee, Stephen Clarke, Thang N Tran, Trina Lum, Po Y Yip,[...]. Histopathology 2017
39
30

Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer.
Caroline E McCoach, Anh T Le, Katherine Gowan, Kenneth Jones, Laura Schubert, Andrea Doak, Adriana Estrada-Bernal, Kurtis D Davies, Daniel T Merrick, Paul A Bunn,[...]. Clin Cancer Res 2018
136
12


Screening for ALK in non-small cell lung carcinomas: 5A4 and D5F3 antibodies perform equally well, but combined use with FISH is recommended.
Spasenija Savic, Joachim Diebold, Anne-Katrin Zimmermann, Wolfram Jochum, Betty Baschiera, Susanne Grieshaber, Luigi Tornillo, Bettina Bisig, Keith Kerr, Lukas Bubendorf. Lung Cancer 2015
64
17

ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer.
Jessica J Lin, Lauren L Ritterhouse, Siraj M Ali, Mark Bailey, Alexa B Schrock, Justin F Gainor, Lorin A Ferris, Mari Mino-Kenudson, Vincent A Miller, Anthony J Iafrate,[...]. J Thorac Oncol 2017
67
16

Detection of ROS1-positive non-small cell lung cancer on cytological specimens using immunocytochemistry.
Tatjana Vlajnic, Spasenija Savic, Audrey Barascud, Betty Baschiera, Michel Bihl, Bruno Grilli, Michelle Herzog, Julien Rebetez, Lukas Bubendorf. Cancer Cytopathol 2018
26
42

Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-Small Cell Lung Cancer.
Ziming Li, Lan Shen, Ding Ding, Jia Huang, Jie Zhang, Zhiwei Chen, Shun Lu. J Thorac Oncol 2018
50
22

High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden.
Ryma Benayed, Michael Offin, Kerry Mullaney, Purvil Sukhadia, Kelly Rios, Patrice Desmeules, Ryan Ptashkin, Helen Won, Jason Chang, Darragh Halpenny,[...]. Clin Cancer Res 2019
205
11

Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
Alexander Drilon, Salvatore Siena, Rafal Dziadziuszko, Fabrice Barlesi, Matthew G Krebs, Alice T Shaw, Filippo de Braud, Christian Rolfo, Myung-Ju Ahn, Jürgen Wolf,[...]. Lancet Oncol 2020
196
11

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
Alice T Shaw, Dong-Wan Kim, Kazuhiko Nakagawa, Takashi Seto, Lucio Crinó, Myung-Ju Ahn, Tommaso De Pas, Benjamin Besse, Benjamin J Solomon, Fiona Blackhall,[...]. N Engl J Med 2013
10

High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung Cancer.
Marcel Wiesweg, Wilfried E E Eberhardt, Henning Reis, Saskia Ting, Nikoleta Savvidou, Charlotte Skiba, Thomas Herold, Daniel C Christoph, Johannes Meiler, Karl Worm,[...]. J Thorac Oncol 2017
46
21

Detection of lung adenocarcinoma with ROS1 rearrangement by IHC, FISH, and RT-PCR and analysis of its clinicopathologic features.
Bing Cao, Ping Wei, Zebing Liu, Rui Bi, Yongming Lu, Ling Zhang, Jing Zhang, Yusi Yang, Chen Shen, Xiang Du,[...]. Onco Targets Ther 2015
34
29

EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations.
Erik Thunnissen, Lukas Bubendorf, Manfred Dietel, Göran Elmberger, Keith Kerr, Fernando Lopez-Rios, Holger Moch, Wlodzimierz Olszewski, Patrick Pauwels, Frédérique Penault-Llorca,[...]. Virchows Arch 2012
163
10

Immunohistochemistry of Pulmonary Biomarkers: A Perspective From Members of the Pulmonary Pathology Society.
Erik Thunnissen, Timothy Craig Allen, Julien Adam, Dara L Aisner, Mary Beth Beasley, Alain C Borczuk, Philip T Cagle, Vera Luiza Capelozzi, Wendy Cooper, Lida P Hariri,[...]. Arch Pathol Lab Med 2018
55
18

Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.
Alexander Drilon, Sai-Hong Ignatius Ou, Byoung Chul Cho, Dong-Wan Kim, Jeeyun Lee, Jessica J Lin, Viola W Zhu, Myung-Ju Ahn, D Ross Camidge, Judy Nguyen,[...]. Cancer Discov 2018
214
10

A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer.
Alexander Drilon, Romel Somwar, Jacob P Wagner, Nadeem A Vellore, Christopher A Eide, Matthew S Zabriskie, Maria E Arcila, Jaclyn F Hechtman, Lu Wang, Roger S Smith,[...]. Clin Cancer Res 2016
106
10

Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial.
Sebastian Michels, Bartomeu Massutí, Hans-Ulrich Schildhaus, Jeremy Franklin, Martin Sebastian, Enriqueta Felip, Christian Grohé, Delvys Rodriguez-Abreu, Diana S Y Abdulla, Helge Bischoff,[...]. J Thorac Oncol 2019
51
19

Detection of ALK-positive non-small-cell lung cancers on cytological specimens: high accuracy of immunocytochemistry with the 5A4 clone.
Spasenija Savic, Beata Bode, Joachim Diebold, Ivo Tosoni, Audrey Barascud, Betty Baschiera, Bruno Grilli, Michelle Herzog, Ellen Obermann, Lukas Bubendorf. J Thorac Oncol 2013
76
11

Comparison of methods in the detection of ALK and ROS1 rearrangements in lung cancer.
Toni-Maree Rogers, Prudence A Russell, Gavin Wright, Zoe Wainer, Jia-Min Pang, Leigh A Henricksen, Shalini Singh, Stacey Stanislaw, James Grille, Esteban Roberts,[...]. J Thorac Oncol 2015
60
15


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.